Secord, A. A., Lee, E. K., Sundborg, M. J., Black, D., Starks, D., Alvarez, E. A., Spigel, D. R., Cloven, N., Knowles, L. M., Melnyk, A., Winter, W., McCollum, M., Soumaoro, I., Liu, Y., Marth, C. (2025). A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5627